德展健康联手中国工程院杨宝峰院士 开展大麻和多肽类药物治疗罕见病及癌症研究

Group 1 - The core point of the article is the collaboration between Dezheng Health and Academician Yang Baofeng to enhance research and development in various medical fields, including cardiovascular diseases, tumors, metabolic system diseases, pulmonary hypertension, and neurological disorders [1][2][3] - The collaboration will involve the establishment of an academician expert workstation within Dezheng Health's subsidiaries, aimed at fostering innovation and improving research capabilities [1][2][3] - Yang Baofeng is a prominent figure in cardiovascular research, having led significant national projects and made notable discoveries in the field, which adds credibility to the partnership [1][2] Group 2 - Dezheng Health has been actively involved in the research of Cannabidiol (CBD) since 2019, with projects targeting pulmonary hypertension, epilepsy, and Parkinson's disease showing promising results [2] - The framework agreement emphasizes the joint focus on industrial hemp-derived cannabinoids and peptide drugs, particularly in the treatment of rare diseases and cancers [2] - The signing of the agreement is seen as a strategic move to strengthen Dezheng Health's innovation-driven development strategy and enhance its market competitiveness [3]